title: Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns.
abstract: BACKGROUND
  Human growth hormone is an anabolic agent that attenuates injury-induced catabolism and stimulates protein synthesis. Recombinant human growth hormone (rhGH) administered therapeutically to patients with massive burns has been shown to increase the rate of skin graft donor site healing. It has been postulated that growth hormone affects wound healing and tissue repair by stimulating the production of insulin-like growth factor-1 (IGF-1) by the liver to increase circulating IGF-1 concentrations. The mechanism by which it improves wound healing, however, remains in question. The authors hypothesize that rhGH up-regulates IGF-1 receptors and IGF-1 levels both systemically and locally in the wound site to stimulate cell mitosis and increase synthesis of laminin, collagen types IV and VII, and cytokeratin. This hypothesis was tested in nine patients with burns covering > 40% of total body surface area.
  
  
  OBJECTIVE
  The authors assessed the efficacy of rhGH in promoting several major building materials in the donor site of patients with massive burns.
  
  
  METHODS
  Ten massively burned patients with full-thickness burns covering more than 40% of total body surface area were participants in a placebo-controlled prospective study to determine the efficacy of 0.2 mg/kg/day rhGH on donor site wound healing and to identify some of the major components involved in wound healing and its integrity.
  
  
  RESULTS
  Donor sites in burn patients receiving rhGH showed an increased coverage by the basal lamina of 26% for placebo to 68% coverage of the dermal-epidermal junction. Insulin-like growth factor-1 receptors and laminin, types IV and VII collagen, and cytokeratin-14 all increased significantly. Healing times of the donor sites were significantly decreased compared with patients receiving placebo.
  
  
  CONCLUSIONS
  Results indicate that growth hormone or its secondary mediators may directly stimulate the cells of the epidermis and dermis during wound healing to produce the structural proteins and other components needed to rebuild the junctional structures.
authors.affiliation: Department of Surgery, University of Texas Medical Branch, Glaveston, USA.
authors.forename: D N
authors.initials: DN
authors.lastname: Herndon
authors.forename: H K
authors.initials: HK
authors.lastname: Hawkins
authors.forename: T T
authors.initials: TT
authors.lastname: Nguyen
authors.forename: E
authors.initials: E
authors.lastname: Pierre
authors.forename: R
authors.initials: R
authors.lastname: Cox
authors.forename: R E
authors.initials: RE
authors.lastname: Barrow
mesh_terms: D000293:Adolescent; D000328:Adult; D002056:Burns / Q000188:drug therapy* / Q000601:surgery*; D002648:Child; D003094:Collagen; D003131:Combined Modality Therapy; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D008854:Microscopy, Electron; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012867:Skin / Q000166:cytology; D016038:Skin Transplantation; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D011994:Recombinant Proteins; D013006:Growth Hormone; D003094:Collagen